3 Results for "

Myc-driven tumorigenesis

" in MedChemExpress (MCE) Product Catalog:
Products (3)

3 Results for "Myc-driven tumorigenesis" in MCE Product Catalog:

19
19 Cited Publications
Cat. No.: HY-112929
CAS No.: 1809427-19-7
Purity:  99.83%
Target:  

Phosphatase

Research Areas:  

Cancer

DT-061 is an orally bioavailable activator of protein phosphatase 2A (PP2A) and could be applied in the therapy of KRAS-mutant and MYC-driven tumorigenesis .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-112929B
CAS No.: 1809427-20-0
Purity:  99.77%
Target:  

Phosphatase

Research Areas:  

Cancer

(1S,2S,3R)-DT-061 is an enantiomer of DT-061 (HY-112929). DT-061 is an orally active activator of protein phosphatase 2A (PP2A). (1S,2S,3R)-DT-061 can be used as a negative control in the research of KRAS-mutant and MYC-driven lung cancer tumorigenesis .
loading...
    loading...
Cat. No.: HY-181541
Research Areas:  

Cancer

HIT211504993 is a selective histone deacetylase 6 (HDAC6) inhibitor with an IC50 of 0.070 μM. HIT211504993 suppresses cancer cell proliferation, cause G1 phase cell cycle arrest and induces apoptosis. HIT211504993 inhibits Myc-driven tumorigenesis via nucleocytoplasmic acetylation, p53 modulation, and Wnt/β-catenin signaling modulation. HIT211504993 inhibits tumor growth in a colon cancer xenograft mouse model. HIT211504993 can be used for the research of colon cancer .
loading...
    loading...